New Products/News of the Industry

Login toDownload PDF version

Faster VLU healing achieved

New comparative effectiveness research demonstrated faster time to healing and improved healing rates with Apligraf (Organogenesis, Canton, MA) for the treatment of venous leg ulcers. The study compared clinical outcomes of the bilayer living cellular construct with an acellular fetal bovine collagen dressing. Using real-world data from Net Health WoundExpert (Pittsburgh, PA), the study found that the bilayer living cellular construct experienced a 37% faster median time to wound closure and a 45% increased probability of healing compared with the bovine collagen dressing.

For more information, visit 

Topical oxygen healing effectiveness demonstrated

The healing effectiveness of topical wound oxygen (TWO2) from AOTI Inc (Oceanside, CA) was demonstrated in 2 study abstracts recently presented at the Symposium on Advanced Wound Care Spring (Charlotte, NC) and the European Wound Management Association (Krakow, Poland).

The study, “A Retrospective Review of Topical Wound Oxygen As An Adjunct Treatment in Healing Chronic Ulcerations,” reviewed 71 patients with 115 wounds of various etiologies that were prescribed cyclical pressurized TWO2 therapy at home. Of the 115 ulcers receiving the treatment, 64.4% achieved complete closure and the majority of wounds that did not reach full closure decreased in size after starting TWO2 therapy.

For more information, visit 

Positive outcomes achieved using wound autograft 

Reapplix ApS (Birkerød, Denmark) presented positive outcome data from an independent randomized controlled trial (RCT) of its LeucoPatch wound healing platform (also marketed as 3CPatch in the United States) at the American Diabetes Association 78th Scientific Sessions (Orlando, FL). This observer-blinded RCT demonstrated that patients treated with an application of the platform in addition to standard of care had a 58% increased chance of healing. 

The platform is a novel technology that uses cells and growth factors from a sample of a patient’s blood to produce a “patch” at the point of care. This patch, without reagents or additives, then is applied topically for the management of exuding cutaneous wounds.

For more information, visit 

Enrollment complete for phase 3 study

The enrollment for a United States Food and Drug Administration Phase 3 study is now complete for NexoBrid (MediWound Ltd, Yavne, Israel), with data expected in the final months of 2018. The DETECT study is a prospective, controlled, multinational, blinded Phase 3 study with 175 patients randomized to either treatment with the eschar removal agent, gel vehicle, or standard of care. This latest trial will evaluate the efficacy and safety of the eschar removal agent in hospitalized patients with severe burns by studying complete eschar removal; its secondary endpoints include reduction in surgical burden and blood loss as well as early eschar removal. The study is fully funded by the Biomedical and Advanced Research and Development Authority (Washington, DC). 

For more information, visit 

Briefing published on single-use NPWT

The National Institute for Health and Care Excellence (NICE; London, UK) issued a Medtech Innovation Briefing on the use of PICO Single Use Negative Pressure Wound Therapy (sNPWT, Smith & Nephew). This briefing, released by NICE as educational material for British clinicians, reports how the prophylactic use of the sNPWT can be an effective alternative to standard of care in the prevention of surgical site complications. This new briefing is the first and only one of its kind on any sNPWT device.

For more information, visit 

New mobile app for nurses now available

A new online professional community brings together wound care nurses through the Nurses2Nurses mobile application by KCI, an Acelity Company (San Antonio, TX). The app is a HIPAA-compliant, closed clinical community where nurses can ask questions and share credible insight and information with their peers. Conversations on the platform are managed by wound care nurses and moderators. The platform was launched in June at the 2018 Annual Conference of the Wound Ostomy and Continence Nurses Society. 

For more information,visit

Strategic wound care partnership established

Kent Imaging Inc (Calgary, Alberta, Canada) and SerenaGroup (Hingham, MA) announced a new strategic partnership to improve wound assessment. With the partnership, the SerenaGroup will incorporate near infrared imaging technology with the KD203 device (Kent Imaging) into group member clinics.

The device is a noninvasive tissue oxygenation measurement system that reports saturation, relative oxyhemoglobin, and relative deoxyhemoglobin levels in superficial tissue. These measurements produce a 2-dimesional, color-coded image to provide clinicians with critical information on at-risk tissue and to help guide treatment to optimize patient outcomes.

For more information. visit 

Prep course trains hospital personnel

The Rehabilitation Hospital of Northern Arizona (Flagstaff, AZ) used the Wound Certification Prep Course by HMP (Malvern, PA) to train its health care personnel. In a private course for 25 providers, the 2-day course reviewed wound healing strategies and topical therapeutic interventions and prepared participants for future wound care certification examinations.

The preparation course is the only review course recommended by the American Board of Wound Management (Washington, DC).

For more information, visit 

Acquisition expands wound care portfolio

Acelity L.P. Inc (San Antonio, TX) has acquired Crawford Healthcare (Doylestown, PA) and all of its assets. The terms of the agreement were not disclosed. This newest acquisition gives Acelity an expansive portfolio of advanced wound dressings, including the superabsorbent KerraMax Care range as well as the KerraFoam and KerraCel foam and antimicrobial gelling fiber dressings (Crawford). These products will complement a portfolio that already includes PROMOGRAN PRISMA matrices, TIELLE dressings, and ADAPTIC dressings (Acelity). In addition to the products, the acquisition includes Crawford’s research and development capabilities and manufacturing operations based in Cheshire, United Kingdom.

For more information, visit 

This article was not subject to the Ostomy Wound Management peer-review process.